^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD1 inhibitor

    Related drugs:
    17h
    Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • urelumab (BMS-663513)
    18h
    Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Sir Run Run Shaw Hospital
    New P2 trial
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr)
    20h
    A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy (clinicaltrials.gov)
    P2, N=20, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Apr 2026 --> Dec 2027
    Trial primary completion date • Minimal residual disease • Circulating tumor DNA
    |
    Signatera™
    |
    Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)
    21h
    LaPemERLA: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Centre, Singapore | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • letrozole
    21h
    Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma (clinicaltrials.gov)
    P2, N=20, Suspended, M.D. Anderson Cancer Center | Not yet recruiting --> Suspended
    Trial suspension
    |
    Keytruda (pembrolizumab) • zanzalintinib (XL092)
    21h
    CheckMate 9DW: A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=732, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Nov 2026 --> Jul 2026 | Trial primary completion date: Nov 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sorafenib • Lenvima (lenvatinib)
    24h
    MONAMI: Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Assistance Publique - Hôpitaux de Paris | N=43 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Tumor mutational burden • dMMR • First-in-human
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    volrustomig (MEDI5752) • monalizumab (IPH2201)
    24h
    Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=13, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative
    |
    capecitabine • Libtayo (cemiplimab-rwlc)
    1d
    Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=35, Completed, Beth Israel Deaconess Medical Center | Active, not recruiting --> Completed
    Trial completion • IO biomarker
    |
    pidilizumab (CT-011)
    1d
    Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Emory University | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Mar 2028 --> Mar 2029
    Trial completion date • Trial primary completion date • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS G12C • KRAS G12
    |
    Opdivo (nivolumab) • Avmapki (avutometinib) • Fakzynja (defactinib) • ABP 206 (nivolumab biosimilar)
    1d
    NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=29, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • NT219
    1d
    FRAPPE: Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Mayo Clinic | Trial completion date: Jul 2027 --> Jun 2028 | Trial primary completion date: Jul 2027 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Keytruda (pembrolizumab)